Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 20, Number 5—May 2014
Research

Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

Suzanne M. MarksComments to Author , Jennifer Flood, Barbara Seaworth, Yael Hirsch-Moverman, Lori Armstrong, Sundari Mase, Katya Salcedo, Peter Oh, Edward A. Graviss, Paul W. Colson, Lisa Armitige, Manuel Revuelta, Kathryn Sheeran, and the TB Epidemiologic Studies Consortium
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.M. Marks, L. Armstrong, S. Mase, TB Epidemiologic Studies Consortium); California Department of Public Health, Richmond, California, USA (J. Flood, K. Salcedo, P. Oh); Texas Department of State Health Services, Tyler, Texas, USA (B. Seaworth, L. Armitige, K. Sheeran); University of Texas Health Science Center, Tyler (B. Seaworth, L. Armitige, K. Sheeran); ICAP/Columbia University, New York, New York, USA (Y. Hirsch-Moverman, P.W. Colson, M. Revuelta); Methodist Hospital Research Institute, Houston, Texas, USA (E.A. Graviss)

Main Article

Table 3

Clinical characteristics of study participants and other patients with MDR and/or XDR TB, United States, 2005–2007*

Characteristic Study participants, no. (%), n = 135 All US MDR TB patients, no. (%), n = 370
History of LTBI, % of 130 known 21 (16)
History of completing LTBI Rx, % of 21 with history of LTBI 14 (67)
History of TB disease† 48 (36) 60 (16)
Contact with infectious TB patient, % of 87 known 10 (11)
Contact with infectious MDR TB patient, % of 10 contacts 6 (60)
Dead at TB diagnosis 1 (1) 5 (1)
Smear positive at any time, % of 134 alive at diagnosis†
 103 (77)
 223 (60)
Sites of TB disease
Pulmonary 115 (85) 332 (90)
Extrapulmonary only 8 (6) 37 (10)
Disseminated at any time
 12 (9)
Extent of pulmonary disease at diagnosis
Extensive 69
Moderate 31
Minimal 21
Undocumented
6
Description of extensive pulmonary disease, at any time
Miliary 4
Cavitary 58 127
Multiple lobes 70
Collapsed lobes
 6
Extent of extrapulmonary disease at diagnosis
Extensive 2
Moderate 3
Minimal
3
*MDR, multidrug resistant; XDR, extensively drug resistant; TB, tuberculosis; LTBI, latent TB infection; Rx, treatment. Blank cells indicate data not available.
†Statistically significant differences between percentages of study patients and all US MDR TB patients at p<0.05.

Main Article

Page created: April 16, 2014
Page updated: April 16, 2014
Page reviewed: April 16, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external